XL t(11;14) MYEOV/IGH DF

Translocation/Dual Fusion Probe

Order Number
Package Size
100 µl


XL t(11;14) MYEOV/IGH DF

XL t(11;14) MYEOV/IGH DF is designed as a dual fusion probe. The orange labeled probe flanks the breakpoint at 11q13 (MYEOV), the green labeled probe flanks the IGH breakpoint region at 14q32.

Clinical Details

The mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with an aggressive clinical course. It is genetically characterized by t(11;14)(q13;q32) and is present in about 95% of MCL patients. By lower frequency, t(11;14) is also detectable in B-cell prolymphocytic leukemia, myelomas and chronic lymphocytic leukemia. The translocation induces overexpression of CCND1 which is normally not detected in B lymphocytes. CCND1 is a major player in cell cycle regulation and involved in the G1/S-phase transition. The oncogenic potential of CCDN1 overexpression is related to its role in the cell cycle but also to other, non-cell cycle-related mechanisms as increased genomic instability and cell survival. t(11;14) is considered as a primary event, often followed by secondary chromosome alterations.
In multiple myeloma (MM), t(11;14) is the most common translocation, detectable in about 15-20% of all MM patients by FISH. Conventional cytogenetics has a much lower sensitivity, detecting t(11;14) in about 5% of MM patients. MM t(11;14) patients do have a relatively favorable outcome compared to other recurrent IGH translocations.

Clinical Applications

  • Non-Hodgkin Lymphomas (NHL)
  • Multiple Myeloma and Plasma Cell Neoplasms (MM)
  • Chronic Lymphocytic Leukemia (CLL)


XL t(11;14) MYEOV/IGH DF

XL t(11;14) IGH/MYEOV DF hybridized to lymphocytes. One normal metaphase and one normal interphase are shown.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.


  • Fonesca et al (2002) Blood 99:3735-3741
  • Bentz et al (2004) Canc Cytopath 102:124-131
  • Jares et al (2012) J Clin Invest 122:3416-3423


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.